Want to see JP:4263 full AI Analyst Report?
4263 Stock Chart & Stats
¥821.00
¥24.00(3.84%)
At close: 4:00 PM EST
¥821.00
¥24.00(3.84%)
Day’s Range― - ―
52-Week Range¥587.00 - ¥1,231.00
Previous CloseN/A
Volume269.90K
Average Volume (3M)121.17K
Market Cap
¥13.73B
Enterprise Value¥8.74B
Total Cash (Recent Filing)¥4.40B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.79
Shares Outstanding16,868,100
10 Day Avg. Volume117,240
30 Day Avg. Volume121,170
Financial Highlights & Ratios
PEG Ratio2.02
Price to Book (P/B)2.35
Price to Sales (P/S)22.16
P/FCF Ratio-23.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)46.6
Revenue Forecast (FY)¥2.20B
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt and roughly ¥4.37B equity materially lower financial risk and give management flexibility to fund operations or invest in product development. This improves runway and strategic optionality over the next 2–6 months even while profitability recovers.
Exceptionally High Gross MarginsNear-97% gross margins indicate the core offering is highly scalable with low incremental cost. Structurally, that supports operating leverage as revenue grows, enabling potential rapid margin expansion once fixed operating costs are controlled, a durable advantage for the business model.
Revenue Growth Resumed In 2025Return to positive top-line growth after a prior decline suggests stabilization in demand or improved adoption of offerings. If sustained, even modest revenue growth can materially reduce burn given high gross margins and provide a platform for scaling sales and improving unit economics over the medium term.
Bears Say
Rising Cash BurnNegative and worsening operating and free cash flow demonstrate increasing cash consumption. Even with no debt, sustained negative cash flow pressures liquidity and can force dilution, spending cuts, or delays in strategic initiatives if revenue and cost trajectories don't improve within months.
Deep Ongoing UnprofitabilityPersistent large negative net margins and negative EBIT/EBITDA show costs materially outpace revenue. Even with margin improvement, sustained unprofitability undermines return generation and requires ongoing funding, limiting ability to self-finance growth and adding execution risk over the coming quarters.
Weak Longer-term Growth And ReturnsMulti-year declines in revenue and EPS growth metrics indicate structural challenges scaling revenue and converting it to earnings. Declining equity and negative ROE history further show returns are negative, increasing the likelihood management must secure capital or materially restructure costs.
4263 FAQ
What was SUSMED,Inc.’s price range in the past 12 months?
SUSMED,Inc. lowest stock price was ¥587.00 and its highest was ¥1231.00 in the past 12 months.
What is SUSMED,Inc.’s market cap?
SUSMED,Inc.’s market cap is ¥13.73B.
When is SUSMED,Inc.’s upcoming earnings report date?
SUSMED,Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 37 days.
How were SUSMED,Inc.’s earnings last quarter?
SUSMED,Inc. released its earnings results on May 08, 2026. The company reported -¥3.54 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.54.
Is SUSMED,Inc. overvalued?
According to Wall Street analysts SUSMED,Inc.’s price is currently Overvalued.
Does SUSMED,Inc. pay dividends?
SUSMED,Inc. does not currently pay dividends.
What is SUSMED,Inc.’s EPS estimate?
SUSMED,Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SUSMED,Inc. have?
SUSMED,Inc. has 16,868,100 shares outstanding.
What happened to SUSMED,Inc.’s price movement after its last earnings report?
SUSMED,Inc. reported an EPS of -¥3.54 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.611%.
Which hedge fund is a major shareholder of SUSMED,Inc.?
Currently, no hedge funds are holding shares in JP:4263
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SUSMED,Inc.
SUSMED,Inc. develops and sells therapeutic applications in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. It also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, the company offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.